Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy.

Biomaterials

Laboratory of Nanomedicine, Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar 751023, Orissa, India.

Published: May 2010

AI Article Synopsis

  • Chemotherapeutic drugs often harm healthy tissues due to their lack of specificity, prompting the development of drug-loaded multifunctional magnetic nanoparticles (MNPs) for better treatment.
  • These glycerol monooleate coated magnetic nanoparticles (GMO-MNPs) demonstrated high drug entrapment efficiency (around 95%) and sustained release for over two weeks, confirming biocompatibility through various testing methods.
  • The addition of HER2 antibodies to the GMO-MNPs significantly improved drug uptake in breast cancer cells (MCF-7), suggesting their potential as an effective targeted drug delivery system in cancer therapy.

Article Abstract

The primary inadequacy of chemotherapeutic drugs is their relative non-specificity and potential side effects to the healthy tissues. To overcome this, drug loaded multifunctional magnetic nanoparticles are conceptualized. We report here an aqueous based formulation of glycerol monooleate coated magnetic nanoparticles (GMO-MNPs) devoid of any surfactant capable of carrying high payload hydrophobic anticancer drugs. The biocompatibility was confirmed by tumor necrosis factor alpha assay, confocal microscopy. High entrapment efficiency approximately 95% and sustained release of encapsulated drugs for more than two weeks under in vitro conditions was achieved for different anticancer drugs (paclitaxel, rapamycin, alone or combination). Drug loaded GMO-MNPs did not affect the magnetization properties of the iron oxide core as confirmed by magnetization study. Additionally the MNPs were functionalized with carboxylic groups by coating with DMSA (Dimercaptosuccinic acid) for the supplementary conjugation of amines. For targeted therapy, HER2 antibody was conjugated to GMO-MNPs and showed enhanced uptake in human breast carcinoma cell line (MCF-7). The IC(50) doses revealed potential antiproliferative effect in MCF-7. Therefore, antibody conjugated GMO-MNPs could be used as potential drug carrier for the active therapeutic aspects in cancer therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2010.01.057DOI Listing

Publication Analysis

Top Keywords

drug loaded
12
iron oxide
8
cancer therapy
8
magnetic nanoparticles
8
anticancer drugs
8
antibody conjugated
8
conjugated gmo-mnps
8
dual drug
4
loaded superparamagnetic
4
superparamagnetic iron
4

Similar Publications

Palladium-Catalyzed Stereospecific Glycosylation Enables Divergent Synthesis of N-O-Linked Glycosides.

Org Lett

January 2025

Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chemical Biology Research Center, School of Pharmaceutical Sciences, Chongqing University, Chongqing 401331, People's Republic of China.

We present a versatile palladium-catalyzed glycosylation platform that enables facile access to structurally diverse N-O-linked glycosides with constantly excellent regio- and stereoselectivities. Importantly, this approach offers a broad substrate scope, low catalyst loadings, and outstanding chemoselectivity, allowing for the selective reaction of oximes/hydroximic acids over hydroxyl groups that would otherwise pose challenges in conventional glycosylation methods. The synthetic utility of this method is further exemplified through a range of synthetic transformations and late-stage modification of bioactive molecules.

View Article and Find Full Text PDF

In Brazil, Visceral Leishmaniases is caused by Leishmania infantum, and domestic dogs are the main reservoirs in its urban transmission cycle. As an alternative to euthanizing dogs, miltefosine has been used to treat canine visceral leishmaniasis since 2016. In this study, we have assessed the efficacy of miltefosine for treating canine visceral leishmaniasis in a new endemic area through follow-up of naturally infected dogs was evaluated.

View Article and Find Full Text PDF

Controlled-release microparticles offer a promising avenue for enhancing patient compliance and minimizing dosage frequency. In this study, we aimed to design controlled-release microparticles of Glipizide utilizing Eudragit S100 and Methocel K 100 M polymers as controlling agents. The microparticles were fabricated through a simple solvent evaporation method, employing various drug-to-polymer ratios to formulate different controlled-release batches labeled as F1 to F5.

View Article and Find Full Text PDF

Thermo-responsive Fluorescent Nanopolymer Delivery Platform for Treatment of Diffuse Large B-cell Lymphoma (DLBCL).

J Fluoresc

January 2025

Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, China.

Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive diffuse malignant proliferative disease of the lymphatic system. Patients usually present with progressive lymph node enlargement and/or extra-lymph node lesions and require early treatment upon diagnosis. Most of the patients are in stage III or IV at the time of diagnosis and about 40% of the patients are difficult to cure.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is the most frequent cause of dementia. Since there are complex pathophysiological mechanisms behind AD, and there is no effective treatment strategy, it is necessary to introduce novel multi-targeting agents with fewer side effects and higher efficacy. Polydatin (PD) is a naturally occurring resveratrol glucoside employing multiple mechanisms toward neuroprotection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!